Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with clinical testing of its Category 1 biologic product, SHR-1681.
Novel Biologic Product SHR-1681
The product, SHR-1681, is designed to specifically bind to antigens present on the surface of tumor cells. Following binding, the product is internalized and transported to lysosomes, where it induces tumor cell death. This mechanism of action represents a potentially groundbreaking approach in cancer treatment. Notably, no similar product has been approved worldwide, and the specific target of SHR-1681 remains undisclosed, adding to the intrigue surrounding this new therapeutic candidate.-Fineline Info & Tech
